Abstract
Our preliminary experience shows that flutamide is an effective treatment in patients with stage C and D prostate cancer. Local and distant response rates appear to be comparable with those obtained by "classic" hormone therapy. Libido and sexual potency are generally not affected. Palliation of symptoms is frequent and is usually accompanied by improvement of performance status and quality of life. The side effects are slight or moderate, but an elevation of transaminases in patients with borderline liver insufficiency is possible.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Review
MeSH terms
-
Aged
-
Aged, 80 and over
-
Anilides / therapeutic use*
-
Combined Modality Therapy
-
Diethylstilbestrol / adverse effects
-
Diethylstilbestrol / therapeutic use
-
Drug Evaluation
-
Erectile Dysfunction / chemically induced
-
Erectile Dysfunction / prevention & control
-
Flutamide / therapeutic use*
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Gonadotropin-Releasing Hormone / antagonists & inhibitors
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / therapeutic use*
-
Imidazolidines*
-
Italy
-
Libido / drug effects
-
Male
-
Middle Aged
-
Multicenter Studies as Topic
-
Neoplasms, Hormone-Dependent / blood
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / surgery
-
Orchiectomy
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / surgery
-
Quality of Life
-
Testosterone / blood
Substances
-
Anilides
-
Imidazoles
-
Imidazolidines
-
Gonadotropin-Releasing Hormone
-
Testosterone
-
nilutamide
-
Diethylstilbestrol
-
Flutamide